Investigating hormone signaling and protein synthesis in advanced prostate cancer
Official title: Hormone signaling and translation control in advanced prostate cancer
Funded at Fred Hutchinson Cancer Center · NIH-11007160 · Data updated 2026-11-12
This study is looking at how certain hormones and proteins affect advanced prostate cancer, especially a tough type called androgen receptor-low castration resistant prostate cancer, to find new ways to help treat patients better.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $433,940 |
| NIH project number | 5R37CA230617-08 |
| Project ID | NIH-11007160 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are American men diagnosed with advanced prostate cancer, particularly those with androgen receptor-low CRPC.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not have androgen receptor-low CRPC may not benefit from this research.
What this research studies
This research focuses on understanding how hormone signaling and the control of protein synthesis contribute to advanced prostate cancer, particularly a lethal form known as androgen receptor-low castration resistant prostate cancer (CRPC). The researchers have developed new models to study this aggressive cancer type and are exploring the mechanisms that drive its growth. By examining how specific mRNA networks are translated in cancer cells, they aim to uncover new therapeutic targets that could improve treatment outcomes for patients.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that specifically target the mechanisms driving aggressive prostate cancer.
How similar studies have gone: Previous research has shown promise in targeting hormone signaling pathways in prostate cancer, suggesting that this approach may yield significant advancements.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Hsieh, Andrew Caleb — Fred Hutchinson Cancer Center
- Study coordinator: Hsieh, Andrew Caleb
Related research
Other NIH-funded projects on the same topics.
-
Drug that blocks tumor-made male hormones and the androgen receptor for advanced prostate cancer
A new medicine aims to block both the androgen receptor and the tumor’s own production of male hormones to help men with advanced, treatment‑resistant prostate cancer.
-
Boosting a tumor-suppressing enzyme to fight advanced prostate cancer
A research grant aims to develop new molecules that enhance the PP2A enzyme to slow or stop progression of advanced prostate cancer.
-
Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer
A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.
-
Genomic clues to guide therapy in advanced prostate cancer
This grant looks at how a patient’s tumor and germline DNA could predict which targeted or immune therapies will work best for advanced prostate cancer.
-
DACH1-based test to predict therapy response in advanced prostate cancer
A new test using DACH1 and other markers on prostate cancer tissue aims to predict which patients will respond to therapy and guide clinical trials.
-
Understanding how doctors choose treatments to improve advanced prostate cancer care
A clinician-researcher at Duke is exploring how medical decisions are made in advanced prostate cancer to help patients get better, fairer care.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.